FTC Flags 100+ Drug Patents for Improper Orange Book Listings
- November 10, 2023
The Federal Trade Commission (FTC) is challenging more than 100 patents for drug products such as brand-name asthma inhalers and EpiPens as improperly listed in the Food and Drug Administration’s (FDA’s) “Orange Book.”
ARTICLE TAGS
You must be logged in to access this content.